A Phase 1, Open-label, Parallel-group Study to Evaluate the Single-dose Pharmacokinetics of Telotristat Ethyl in Male and Female Subjects With Severe Hepatic Impairment and Matched Subjects With Normal Hepatic Function
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Malignant carcinoid syndrome
- Focus Pharmacokinetics
- Sponsors Lexicon Pharmaceuticals
- 11 Oct 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2018 Planned primary completion date changed from 1 Apr 2018 to 1 Jul 2018.
- 13 Jun 2018 Status changed from recruiting to active, no longer recruiting.